PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11286477-1	2001	Dexrazoxane combined with doxorubicin (+ 5-fluorouracil + cyclophosphamide - the FAC regime) leads to a significant decrease in doxorubicin cardiotoxicity and a significant increase in median survival time for patients with advanced breast cancer responsive to FAC.	Dexrazoxane	0-11	FA complementation group C	Homo sapiens	81-84	
11286477-1	2001	Dexrazoxane combined with doxorubicin (+ 5-fluorouracil + cyclophosphamide - the FAC regime) leads to a significant decrease in doxorubicin cardiotoxicity and a significant increase in median survival time for patients with advanced breast cancer responsive to FAC.	Dexrazoxane	0-11	FA complementation group C	Homo sapiens	261-264	
11286477-10	2001	These results suggest that dexrazoxane may delay the development of MDR1, thus allowing responders to the FAC regime to continue to respond.	Dexrazoxane	27-38	FA complementation group C	Homo sapiens	106-109